Latest news
{{'Mon, 16 Nov 2026 17:00:00 -0500' | dateFormatUsFilter}}
Novo presents preclinical and human data suggesting a role for amylin and calcitonin receptor activation in preserving bone during weight loss at ObesityWeek®
Read more
{{'Mon, 16 Nov 2026 10:00:00 -0500' | dateFormatUsFilter}}
Wegovy® resulted in a BMI reduction of 10% or more in almost 80% of children with obesity aged 6 to under 12, compared to 0% with placebo in STEP Young trial, published in The New England Journal of Medicine
Read more
{{'Sun, 15 Nov 2026 08:00:00 -0500' | dateFormatUsFilter}}
Novo’s CagriSema was associated with 25% mean weight loss among early responders in a post hoc analysis of REDEFINE 1 presented at ObesityWeek® 2026
Read more
Latest on compounded and counterfeit products and other important information about semaglutide.